Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 25
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • COVID-19 Disease Map Community
Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms

  • Ostaszewski, Marek
  • Niarakis, Anna
  • Mazein, Alexander
  • Kuperstein, Inna
  • Phair, Robert
  • Orta-Resendiz, Aurelio
  • Singh, Vidisha
  • Aghamiri, Sara Sadat
  • Acencio, Marcio Luis
  • Glaab, Enrico
  • Ruepp, Andreas
  • Schreiber, Falk
  • Montagud, Arnau
  • Ponce de León, Miguel
  • Funahashi, Akira
  • Hiki, Yusuke
  • Hiroi, Noriko
  • Yamada, Takahiro G.
  • Dräger, Andreas
  • Renz, Alina
  • Naveez, Muhammad
  • Orlic-Milacic, Marija
  • Bocskei, Zsolt
  • Messina, Francesco
  • Börnigen, Daniela
  • Fergusson, Liam
  • Conti, Marta
  • Rameil, Marius
  • Nakonecnij, Vanessa
  • Vanhoefer, Jakob
  • Schmiester, Leonard
  • Wang, Muying
  • Senff Ribeiro, Andrea
  • Ackerman, Emily E.
  • Shoemaker, Jason E.
  • Zucker, Jeremy
  • Oxford, Kristie
  • Teuton, Jeremy
  • Kocakaya, Ebru
  • Summak, Gökçe Yagmu
  • Hanspers, Kristina
  • Kutmon, Martina
  • Coort, Susan
  • Rothfels, Karen
  • Eijssen, Lars
  • Ehrhart, Friederike
  • Arokia Balaya Rex, Devasahayam
  • Slenter, Denise
  • Martens, Marvin
  • Pham, Nhung
  • Haw, Robin
  • Jassal, Bijay
  • Matthews, Lisa
  • Shamovsky, Veronic
  • Stephan, Ralf
  • Sevilla, Cristoffer
  • Varusai, Thawfeek
  • Ravel, Jean-Marie
  • Fraser, Rupsha
  • Ortseifen, Vera
  • Soliman, Sylvain
  • Marchesi, Silvia
  • Gawron, Piotr
  • Smula, Ewa
  • Heirendt, Laurent
  • Satagopam, Venkata
  • Wu, Guanming
  • Riutta, Anders
  • Golebiewski, Martin
  • Owen, Stuart
  • Goble, Carole
  • Valdeolivas, Alberto
  • Hu, Xiaoming
  • Overall, Rupert W.
  • Maier, Dieter
  • Bauch, Angela
  • Gyori, Benjamin M.
  • Bachman, John A.
  • Vega, Carlos
  • Groues, Valentin
  • Vázquez, Miguel
  • Porras, Pablo
  • Esteban-Medina, Marina
  • Licata, Luana
  • Iannuccelli, Marta
  • Sacco, Francesca
  • Nesterova, Anastasia
  • Yuryev, Anton
  • Waard, Anita de
  • Turei, Denes
  • Luna, Augustín
  • Babur, Ozgun
  • Peña-Chilet, María
  • Rian, Kinza
  • Helikar, Tomas
  • Lal Puniya, Bhanwar
  • Modos, Dezso
  • Treveil, Agatha
  • Olbe, Marton
  • Fobo, Gisela
  • De Meulder, Bertrand
  • Ballereau, Stephane
  • Dugourd, Aurelien
  • Naldi, Aurelien
  • Noël, Vincent
  • Calzone, Laurence
  • Sander, Chris
  • Demir, Emek
  • Korcsmaros, Tamas
  • Freeman, Tom C.
  • Montrone, Corinna
  • Auge, Franck
  • Beckmann, Jacques S.
  • Hasenauer, Jan
  • Wolkenhauer, Olaf
  • Wilighagen, Egon L .
  • Pico, Alexander R.
  • Evelo, Chris T.
  • Gillespie, Marc E.
  • Stein, Lincoln D.
  • Hermjakob, Henning
  • Brauner, Barbara
  • D’Eustachio, Peter
  • Sáez-Rodríguez, Julio
  • Dopazo, Joaquín
  • Valencia, Alfonso
  • Kitano, Hiroaki
  • Barillot, Emmanuel
  • Auffray, Charles
  • Balling, Rudi
  • Schneider, Reinhard
  • Frishman, Goar
  • Monraz Gómez, Luis Cristóbal
  • Somers, Julia
  • Hoch, Matti
  • Gupta, Shailendra Kumar
  • Scheel, Julia
  • Borlinghaus, Hanna
  • Czauderna, Tobias
We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS-CoV-2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large-scale community effort to build an open access, interoperable and computable repository of COVID-19 molecular mechanisms. The COVID-19 Disease Map (C19DMap) is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph-based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS-CoV-2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID-19 or similar pandemics in the long-term perspective., This study was supported by the Luxembourg National Research Fund (FNR) COVID-19 Fast-Track grant programme, grant COVID-19/2020-1/14715687/CovScreen (E. Glaab); European Commission, INFORE grant H2020-ICT-825070 (A. Montagud, M. Ponce de Leon, M. Vazques and A. Valencia); European Commission, PerMedCoE grant H2020-ICT-951773 (A. Montagud, M. Ponce de Leon, M. Vazques and A. Valencia) the Federal Ministry of Education and Research (BMBF, Germany) and the Baden-Württemberg Ministry of Science, the Excellence Strategy of the German Federal and State Governments (A. Renz); German Center for Infection Research (DZIF), grant no 8020708703 (A. Dräger); The Netherlands Organisation for Health Research and Development (ZonMw), grant no 10430012010015, (M. Kutmon, S. Coort, F. Ehrhart, N. Pham, E.L. Willighagen, C.T. Evelo); H2020 Marie Skłodowska-Curie Actions, grant number 765274 (J. Scheel); National Institutes of Health, USA (NIH), grant number U41 HG003751 (L.D. Stein). The development of Reactome is supported by grants from the US National Institutes of Health (U41 HG003751) and the European Molecular Biology Laboratory.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Ostaszewski, Marek
  • Mazein, Alexander
  • Kuperstein, Inna
  • Kutmon, Martina
  • Gillespie, Marc E.
  • Funahashi, Akira
  • Acencio, Marcio Luis
  • Hemedan, Ahmed
  • Aichem, Michael
  • Klein, Karsten
  • Czauderna, Tobias
  • Burtscher, Felicia
  • Yamada, Takahiro G.
  • Hiki, Yusuke
  • Hiroi, Noriko F.
  • Hu, Finterly
  • Pham, Nhung
  • Ehrhart, Friederike
  • Willighagen, Egon L.
  • Valdeolivas, Alberto
  • Dugourd, Aurelien
  • Messina, Francesco
  • Esteban-Medina, Marina
  • Peña-Chilet, María
  • Rian, Kinza
  • Soliman, Sylvain
  • Aghamiri, Sara Sadat
  • Lal Puniya, Bhanwar
  • Naldi, Aurelien
  • Helikar, Tomas
  • Singh, Vidisha
  • Fariñas Fernández, Marco
  • Bermudez, Viviam
  • Tsirvouli, Eirini
  • Montagud, Arnau
  • Noël, Vincent
  • Ponce de León, Miguel
  • Maier, Dieter
  • Bauch, Angela
  • Gyori, Benjamin M.
  • Bachman, John A.
  • Luna, Augustin
  • Piñero, Janet
  • Furlong, Laura I.
  • Balaur, Irina BalaurIrina
  • Rougny, Adrien
  • Jarosz, Yohan
  • Overall, Rupert W.
  • Phair, Robert
  • Perfetto, Livia
  • Matthews, Lisa
  • Balaya Rex, Devasahayam Arokia
  • Orlic-Milacic, Marija
  • Monraz Gómez, Luis Cristóbal
  • De Meulder, Bertrand
  • Ravel, Jean-Marie
  • Jassal, Bijay
  • Satagopam, Venkata
  • Wu, Guanming
  • Golebiewski, Martin
  • Gawron, Piotr
  • Calzone, Laurence
  • Beckmann, Jacques S.
  • Evelo, Chris T.
  • D’Eustachio, Peter
  • Schreiber, Falk
  • Sáez-Rodríguez, Julio
  • Dopazo, Joaquín
  • Kuiper, Martin
  • Valencia, Alfonso
  • Wolkenhauer, Olaf
  • Kitano, Hiroaki
  • Barillot, Emmanuel
  • Auffray, Charles
  • Balling, Rudi
  • Schneider, Reinhard
  • COVID- Disease Map Community the COVID-19 Disease Map Community
© 2024 Niarakis, Ostaszewski, Mazein, Kuperstein, Kutmon, Gillespie, Funahashi, Acencio, Hemedan, Aichem, Klein, Czauderna, Burtscher, Yamada, Hiki, Hiroi, Hu, Pham, Ehrhart, Willighagen, Valdeolivas, Dugourd, Messina, Esteban-Medina, Peña-Chilet, Rian, Soliman, Aghamiri, Puniya, Naldi, Helikar, Singh, Fernández, Bermudez, Tsirvouli, Montagud, Noël, Ponce-de-Leon, Maier, Bauch, Gyori, Bachman, Luna, Piñero, Furlong, Balaur, Rougny, Jarosz, Overall, Phair, Perfetto, Matthews, Rex, Orlic-Milacic, Gomez, De Meulder, Ravel, Jassal, Satagopam, Wu, Golebiewski, Gawron, Calzone, Beckmann, Evelo, D’Eustachio, Schreiber, Saez-Rodriguez, Dopazo, Kuiper, Valencia, Wolkenhauer, Kitano, Barillot, Auffray, Balling, Schneider and the COVID-19 Disease Map Community. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing., Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors., Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19., Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immune digital twins for complex human pathologies: applications, limitations, and challenges

  • Niarakis, Anna
  • Montagud, Arnau
  • Valencia, Alfonso
Niarakis, Anna et al., Digital twins represent a key technology for precision health. Medical digital twins consist of computational models that represent the health state of individual patients over time, enabling optimal therapeutics and forecasting patient prognosis. Many health conditions involve the immune system, so it is crucial to include its key features when designing medical digital twins. The immune response is complex and varies across diseases and patients, and its modelling requires the collective expertise of the clinical, immunology, and computational modelling communities. This review outlines the initial progress on immune digital twins and the various initiatives to facilitate communication between interdisciplinary communities. We also outline the crucial aspects of an immune digital twin design and the prerequisites for its implementation in the clinic. We propose some initial use cases that could serve as "proof of concept" regarding the utility of immune digital technology, focusing on diseases with a very different immune response across spatial and temporal scales (minutes, days, months, years). Lastly, we discuss the use of digital twins in drug discovery and point out emerging challenges that the scientific community needs to collectively overcome to make immune digital twins a reality., This work is based on work during the three-week workshop on Building Immune Digital Twins, which was made possible by the support of the Institut Pascal, University of Paris-Saclay, France, via the program Investissements d’avenir, ANR-11-IDEX-0003-0. We would also like to thank Genopole for supporting the workshop. The authors also acknowledge the following support: AN was supported by a public-private partnership grant (CIFRE contract, no. 2020/0766) with SANOFI-AVENTIS R&D. R.L. acknowledges financial support from the Defense Advanced Research Projects Agency (grant HR00112220038), and the National Institutes of Health (grants R01 GM127909, R01 AI135128, and R01 HL169974). L.C.M., B.S., and L.G. acknowledge support from the European Commission (grants H2020-SC1-BHC-11-2020 963845 and Digital Europe EDITH-CSA 101083771). M.L.B. acknowledges support from the National Institutes of Health (grants R24 GM137787 and P41 EB023912). L.L.F. acknowledges financial support from the Defense Advanced Research Projects Agency (grant HR00112220038). L.H. acknowledged support from NIH/NCI Transition Career Development Award to Promote Diversity (K22-CA237857). L.S.V. acknowledges support from the National Institutes of Health (grants R01 AI135128, R01 HL169974, K25 AI175668). P.H. acknowledges support from the Prime Ministers’ Research Fellowship (PMRF). H.B. acknowledges the support of ZonMw (Grant No. 10430012010015) N.N. acknowledges support from the Knowledge Foundation (20200017) and The Swedish Fund for Research Without Animal Experiments. A.M., J.C.C., and A.V. acknowledge support from the European Commission (grants CREXDATA 101092749, PerMedCoE 951773, and EDITH-CSA 101083771). F.M. acknowledges support from the Italian Ministry of Health (grant “Ricerca Corrente” Linea 4 Project 5 and “5 per 1000–2021” Grant No. 5M-2021-23683787) and the European Commission with HORIZON programme (Grant No. 101046203—BY-COVID). J.A.G. acknowledges support from the National Institutes of Health (grants U24 EB028887) and the National Science Foundation (grants NSF 2303695, NSF 2120200, and NSF 1720625). G.A. and C.C. acknowledge support from the National Institutes of Health Award UO1EB025825 and the Defense Advanced Research Projects Agency through Cooperative Agreement D20AC00002 awarded by the U.S. Department of the Interior (DOI), Interior Business Center. K.R. was supported by the BMBF (Federal Ministry of Education and Research) in DAAD project 57616814 (SECAI, School of Embedded and Composite AI) as part of the program Konrad Zuse Schools of Excellence in Artificial Intelligence. Further, KR was supported by the imSAVAR and the CERTAINTY project. imSAVAR received funding from the Innovative Medicine Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL. The CERTAINTY project is funded by the European Union (Grant Agreement 101136379)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Experimentally calibrated multiscale model predicts schedule dependent drug combination effects

  • Hayoun-Mya, Othmane
  • Montagud, Arnau
  • Valencia, Alfonso
  • Ponce-de-Leon, Miguel
Therapeutic synergy emerges from interactions between molecular drug action, intracellular signaling, and tissue-level transport dynamics. We developed a multiscale model integrating these scales to predict schedule-dependent drug combination effect in the AGS cell line. Calibrated solely on single-drug growth curves, the model accurately predicted population-level outcomes of drug combinations without combination-specific training. This demonstrates the model’s capacity to suggest mechanistic multiscale insights into the logic of drug combinations within the AGS cell line, establishing a computational platform for the systematic in silico exploration of virtual multiscale experiments on drug diffusion and dosing schedules. Cross-scale analysis revealed that combination therapy efficacy flows across scales: population-level pharmacokinetics dictate the sequence of molecular target engagement within individual cells, determining collective cell-fate decisions. Our simulations predict that inhibiting the PI3K/AKT axis before MEK is more effective than the reverse order, disabling a pro-survival rebound and locking cells into an apoptotic state. Ultimately, by capturing phenomena that single-scale approaches cannot, this framework generates translationally relevant hypotheses, providing a versatile platform for optimizing drug scheduling, formulation, and combination strategies where matched molecular Boolean models and phenotypic data are available., This work was supported by the European Union’s Horizon Europe Research and Innovation programme projects HANAMI (grant agreement No. 101136269), by the Horizon 2020 projects CREXDATA (grant agreement No. 101092749) and PerMedCoE (grant agreement No. 951773) and by the ERA PerMed project Oncologics (ERAPERMED2020-036). O.H.M. was supported by a predoctoral “AGAUR-FI Joan Oró” fellowship from “Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generaliat de Catalunya i del Fons Europeu Social Plus” (2025 FI-1 01021)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Leveraging training expertise to build capacity in computational personalised medicine

  • Lloret Iglesias, Lara
  • Thomas-Lopez, Daniel
  • Calzone, Laurence
  • Montagud, Arnau
  • Noël, Vincent
  • Ponce-de-Leon, Miguel
  • Ruscone, Marco
  • Valencia, Alfonso
  • Brooksbank, Cath
  • The PermedCoE consortium
The PermedCoE consortium: et al., [Data availability] The competency framework is reproduced in full in this paper as supplementary material and available on the Competency Hub at https://www.ebi.ac.uk/training/. Information on the training resources is available in the PerMedCoE website (https://permedcoe.eu/) and EMBL- EBI Training website (https://www.ebi.ac.uk/training/)., Rapid development of genomic technologies in recent years enables personalised medicine to become an essential part of healthcare. Advanced computational methods are required to extract relevant insights that can be applied in clinical settings. This presents a challenge for clinicians and biomedical researchers, who need specialised training to adopt these tools. Within the context of PerMedCoE, the first European Centre of Excellence in Personalised Medicine, we developed and delivered a competency-based training programme to support professionals in the life sciences to work with modelling and simulation tools that integrate omics data to identify biological processes relevant to disease. We identified a set of required competencies in the field and built a series of career profiles with specific competence levels in these. The competencies and profiles contributed to define the focus and target audience of the training activities delivered: a combination of self-paced learning resources, webinars and online and face-to-face synchronous courses. The outputs of the programme (competencies, career profiles and training materials) can be used by biomedical professionals for their own career development or to train others. In addition, the approach can be adopted by other fields with rapid technological advancements and a constant need to upskill professionals., This work has been supported by the European Union’s Horizon 2020 research and innovation programme under the grant agreement N°951773, which provided funding for PerMedCoE., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms

  • Ostaszewski, Marek
  • Niarakis, Anna
  • Mazein, Alexander
  • Kuperstein, Inna
  • Phair, Robert
  • Montagud, Arnau|||0000-0002-7696-1241
  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Vazquez, Miguel
  • Valencia, Alfonso|||0000-0002-8937-6789
We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS-CoV-2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large-scale community effort to build an open access, interoperable and computable repository of COVID-19 molecular mechanisms. The COVID-19 Disease Map (C19DMap) is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph-based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS-CoV-2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID-19 or similar pandemics in the long-term perspective., We would like to thank Andjela Tatarovic, architect, and Gina Crovetto, a researcher in the field of cancer, for their help with the design of the top-level view diagrams. We would like to acknowledge the Responsible and Reproducible Research (R3) team of the Luxembourg Centre for Systems Biomedicine for supporting the project and providing necessary communication and data sharing resources. The work presented in this paper was carried out using the ELIXIR Luxembourg tools and services. This study was supported by the Luxembourg National Research Fund (FNR) COVID-19 Fast-Track grant programme, grant COVID-19/2020-1/14715687/CovScreen (E. Glaab); European Commission, INFORE grant H2020-ICT-825070 (A. Montagud, M. Ponce de Leon, M. Vazques and A. Valencia); European Commission, PerMedCoE grant H2020-ICT-951773 (A. Montagud, M. Ponce de Leon, M. Vazques and A. Valencia) the Federal Ministry of Education and Research (BMBF, Germany) and the Baden-Württemberg Ministry of Science, the Excellence Strategy of the German Federal and State Governments (A. Renz); German Center for Infection Research (DZIF), grant no 8020708703 (A. Dräger); The Netherlands Organisation for Health Research and Development (ZonMw), grant no 10430012010015, (M. Kutmon, S. Coort, F. Ehrhart, N. Pham, E.L. Willighagen, C.T. Evelo); H2020 Marie Skłodowska-Curie Actions, grant number 765274 (J. Scheel); National Institutes of Health, USA (NIH), grant number U41 HG003751 (L.D. Stein). The development of Reactome is supported by grants from the US National Institutes of Health (U41 HG003751) and the European Molecular Biology Laboratory., Peer Reviewed, "Article signat per més de 50 autors/es: Marek Ostaszewski, Anna Niarakis, Alexander Mazein, Inna Kuperstein, Robert Phair, Aurelio Orta-Resendiz, Vidisha Singh, Sara Sadat Aghamiri, Marcio Luis Acencio, Enrico Glaab, Andreas Ruepp, Gisela Fobo, Corinna Montrone, Barbara Brauner, Goar Frishman, Luis Cristóbal Monraz Gómez, Julia Somers, Matti Hoch, Shailendra Kumar Gupta, Julia Scheel, Hanna Borlinghaus, Tobias Czauderna, Falk Schreiber, Arnau Montagud, Miguel Ponce de Leon, Akira Funahashi, Yusuke Hiki, Noriko Hiroi, Takahiro G Yamada, Andreas Dräger, Alina Renz, Muhammad Naveez, Zsolt Bocskei, Francesco Messina, Daniela Börnigen, Liam Fergusson, Marta Conti, Marius Rameil, Vanessa Nakonecnij, Jakob Vanhoefer, Leonard Schmiester, Muying Wang,Emily E Ackerman, Jason E Shoemaker, Jeremy Zucker, Kristie Oxford, Jeremy Teuton, Ebru Kocakaya, Gökçe Yağmur Summak, Kristina Hanspers, Martina Kutmon, Susan Coort, Lars Eijssen, Friederike Ehrhart, Devasahayam Arokia Balaya,Denise Slenter, Marvin Martens, Nhung Pham, Robin Haw, Bijay Jassal, Lisa Matthews, Marija Orlic-Milacic, Andrea Senff Ribeiro, Karen Rothfels, Veronica Shamovsky, Ralf Stephan, Cristoffer Sevilla, Thawfeek Varusai, Jean-Marie Ravel, Rupsha Fraser, Vera Ortseifen, Silvia Marchesi, Piotr Gawron, Ewa Smula, Laurent Heirendt, Venkata Satagopam, Guanming Wu, Anders Riutta, Martin Golebiewski, Stuart Owen51,Carole Goble, Xiaoming Hu, Rupert W Overall, Dieter Maier, Angela Bauch, Benjamin M Gyori, John A Bachman, Carlos Vega, Valentin Grouès, Miguel Vazquez, Pablo Porras, Luana Licata, Marta Iannuccelli, Francesca Sacco57, Anastasia Nesterova, Anton Yuryev, Anita de Waard, Denes Turei, Augustin Luna, Ozgun Babur, Sylvain Soliman, Alberto Valdeolivas, Marina Esteban-Medina, Maria Peña-Chilet, Kinza Rian, Tomáš Helikar, Bhanwar Lal Puniya, Dezso Modos, Agatha Treveil, Marton Olbei, Bertrand De Meulder, Stephane Ballereau, Aurélien Dugourd, Aurélien Naldi, Vincent Noël, Laurence Calzone, Chris Sander, Emek Demir, Tamas Korcsmaros, Tom C Freeman, Franck Augé, Jacques S Beckmann, Jan Hasenauer, Olaf Wolkenhauer, Egon L Wilighagen, Alexander R Pico, Chris T Evelo, Marc E Gillespie, Lincoln D Stein, Henning Hermjakob, Peter D'Eustachio, Julio Saez-Rodriguez, Joaquin Dopazo, Alfonso Valencia, Hiroaki Kitano, Emmanuel Barillot, Charles Auffray, Rudi Balling, Reinhard Schneider "
UPCommons. Portal del coneixement obert de la UPC
Publicación Contribución de congreso (ConferenceOutput)

BioFVM-X: an MPI+OpenMP 3-D simulator for biological systems

  • Saxena, Gaurav
  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Montagud, Arnau|||0000-0002-7696-1241
  • Vicente Dorca, David
  • Valencia, Alfonso|||0000-0002-8937-6789
Multi-scale simulations require parallelization to address large-scale problems, such as real-sized tumor simulations. BioFVM is a software package that solves diffusive transport Partial Differential Equations for 3-D biological simulations successfully applied to tissue and cancer biology problems. Currently, BioFVM is only shared-memory parallelized using OpenMP, greatly limiting the execution of large-scale jobs in HPC clusters. We present BioFVM-X: an enhanced version of BioFVM capable of running on multiple nodes. BioFVM-X uses MPI+OpenMP to parallelize the generic core kernels of BioFVM and shows promising scalability in large 3-D problems with several hundreds diffusible substrates and ≈ 0.5 billion voxels. The BioFVM-X source code, examples and documentation, are available under the BSD 3-Clause license at https://gitlab.bsc.es/gsaxena/biofvm_x., The research leading to these results has received funding from EU H2020 Programme under the PerMedCoE project, grant agreement number 951773 and the INFORE project, grant agreement number 825070. The authors would like to thank Paul Macklin and Randy Heiland from Indiana University for their constant support and advice regarding BioFVM., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Systems Biology at the giga-scale: large multi-scale models of complex, heterogeneous multicellular systems

  • Montagud, Arnau|||0000-0002-7696-1241
  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Valencia, Alfonso|||0000-0002-8937-6789
Agent-based modelling has proven its usefulness in several biomedical projects by explaining and uncovering mechanisms in diseases. Nevertheless, the scenarios addressed in these models usually consider a small number of cells, lack cell-specific characterisation and dynamic interactions and have a simplistic environment description. Tools that enable scalable, real-sized simulations of biological systems that require complex set-ups are needed to have simulations closer to biomedical scenarios that can capture cell-to-cell heterogeneity and system-wide emerging properties. To deliver simulations at the giga-scale (109 cells), different tools have implemented technologies to run in high-performance computing clusters. We hereby review these efforts and detail the main areas of improvement the field needs to focus on to have simulations that are a step closer to having digital twins, This work has been partially supported by the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE project (H2020-ICT-951773)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Patient-specific Boolean models of signalling networks guide personalised treatments

  • Montagud, Arnau|||0000-0002-7696-1241
  • Béal, Jonas
  • Tobalina, Luis
  • Traynard, Pauline
  • Subramanian, Vigneshwari
  • Valencia, Alfonso|||0000-0002-8937-6789
Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell-line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell-line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology., This work has been partially supported by the European Commission under the PrECISE project (H2020-PHC-668858), the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773), Peer Reviewed, "Article signat per 12 autors/es: Arnau Montagud, Jonas Béal, Luis Tobalina, Pauline Traynard, Vigneshwari Subramanian, Bence Szalai, Róbert Alföldi, László Puskás, Alfonso Valencia, Emmanuel Barillot, Julio Saez-Rodriguez, Laurence Calzone"
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Ostaszewski, Marek
  • Mazein, Alexander
  • Kuperstein, Inna
  • Kutmon, Martina
  • Montagud, Arnau|||0000-0002-7696-1241
  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Valencia, Alfonso|||0000-0002-8937-6789
The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms.Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue-or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No.10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “Away to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH)., Peer Reviewed, "Article signat per més de 50 autors/es: Anna Niarakis, Marek Ostaszewski, Alexander Mazein, Inna Kuperstein, Martina Kutmon, Marc E. Gillespie, Akira Funahashi, Marcio L. Acencio, Ahmed Hemedan, Michael Aichem, Karsten Klein, Tobias Czauderna, Felicia Burtscher, Takahiro G. Yamada, Yusuke Hiki, Noriko F. Hiroi, Finterly Hu, Nhung Pham, Friederike Ehrhart, Egon Willighagen, Alberto Valdeolivas, Aurelien Dugourd, Francesco Messina, Marina Esteban Medina, Maria Peña-Chilet, Kinza Rian, Sylvain Soliman, Sara S. Aghamiri, Bhanwar Lal Puniya, Aurélien Naldi, Tomáš Helikar, Vidisha Singh, Marco Fariñas Fernández, Viviam Bermudez, Eirini Tsirvouli, Arnau Montagud, Vincent Noël, Miguel Ponce De Leon, Dieter Maier, Angela Bauch, Benjamin M. Gyori, John A. Bachman, Augustin Luna, Janet Piñero, Laura I. Furlong, Irina Balaur, Adrien Rougny, Yohan Jarosz, Rupert W. Overall, Robert Phair, Livia Perfetto, Lisa Matthews, Devasahayam Arokia Balaya Rex, Marija Orlic-Milacic, Cristobal Luis, Bertrand De Meulder, Jean M. Ravel, Bijay Jassal, Venkata P. Satagopam, Guanming Wu, Martin Golebiewski, Piotr Gawron, Laurence Calzone, Jacques S. Beckmann, Chris Evelo, Peter D'eustachio, Falk Schreiber, Julio Saez-Rodriguez, Joaquin Dopazo, Martin Kuiper, Alfonso Valencia, Olaf Wolkenhauer, Hiroaki Kitano, Emmanuel Barillot, Charles Auffray, Rudi Balling, Reinhard Schneider "
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Optimizing dosage-specific treatments in a multi-Scale model of a tumor growth

  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Montagud, Arnau|||0000-0002-7696-1241
  • Akasiadis, Charilaos
  • Schreiber, Janina
  • Ntiniakou, Thaleia
  • Valencia, Alfonso|||0000-0002-8937-6789
The emergence of cell resistance in cancer treatment is a complex phenomenon that emerges from the interplay of processes that occur at different scales. For instance, molecular mechanisms and population-level dynamics such as competition and cell–cell variability have been described as playing a key role in the emergence and evolution of cell resistances. Multi-scale models are a useful tool for studying biology at very different times and spatial scales, as they can integrate different processes occurring at the molecular, cellular, and intercellular levels. In the present work, we use an extended hybrid multi-scale model of 3T3 fibroblast spheroid to perform a deep exploration of the parameter space of effective treatment strategies based on TNF pulses. To explore the parameter space of effective treatments in different scenarios and conditions, we have developed an HPC-optimized model exploration workflow based on EMEWS. We first studied the effect of the cells’ spatial distribution in the values of the treatment parameters by optimizing the supply strategies in 2D monolayers and 3D spheroids of different sizes. We later study the robustness of the effective treatments when heterogeneous populations of cells are considered. We found that our model exploration workflow can find effective treatments in all the studied conditions. Our results show that cells’ spatial geometry and population variability should be considered when optimizing treatment strategies in order to find robust parameter sets., This research has received funding from the Horizon 2020 INFORE Project, GA n° 825070 and the Horizon 2020 PerMedCoE Project, GA n° 951773., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks

  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Montagud, Arnau|||0000-0002-7696-1241
  • Noël, Vincent
  • Meert, Annika
  • Pradas, Gerard
  • Barillot, Emmanuel
  • Calzone, Laurence
  • Valencia, Alfonso|||0000-0002-8937-6789
In systems biology, mathematical models and simulations play a crucial role in understanding complex biological systems. Different modelling frameworks are employed depending on the nature and scales of the system under study. For instance, signalling and regulatory networks can be simulated using Boolean modelling, whereas multicellular systems can be studied using agent-based modelling. Herein, we present PhysiBoSS 2.0, a hybrid agent-based modelling framework that allows simulating signalling and regulatory networks within individual cell agents. PhysiBoSS 2.0 is a redesign and reimplementation of PhysiBoSS 1.0 and was conceived as an add-on that expands the PhysiCell functionalities by enabling the simulation of intracellular cell signalling using MaBoSS while keeping a decoupled, maintainable and model-agnostic design. PhysiBoSS 2.0 also expands the set of functionalities offered to the users, including custom models and cell specifications, mechanistic submodels of substrate internalisation and detailed control over simulation parameters. Together with PhysiBoSS 2.0, we introduce PCTK, a Python package developed for handling and processing simulation outputs, and generating summary plots and 3D renders. PhysiBoSS 2.0 allows studying the interplay between the microenvironment, the signalling pathways that control cellular processes and population dynamics, suitable for modelling cancer. We show different approaches for integrating Boolean networks into multi-scale simulations using strategies to study the drug effects and synergies in models of cancer cell lines and validate them using experimental data. PhysiBoSS 2.0 is open-source and publicly available on GitHub with several repositories of accompanying interoperable tools., The authors thank Paul Macklin and Randy Heiland for their support with the PhysiCell code and discussions. The authors acknowledge the technical expertise and assistance provided by the Spanish Supercomputing Network (Red Española de Supercomputación), as well as the computer resources used: the LaPalma Supercomputer (RES-BCV-2019-2-0008), located at the Instituto de Astrofísica de Canarias, and MareNostrum4 (RES-BCV-2019-2-0013, RES-BCV-2020-3-0016, RES-BCV-2021-2-0020), located at the Barcelona Supercomputing Center. This work has received funding from the Horizon 2020 projects: INFORE (ID: 825070), PerMedCoE (ID: 951773) and CREXDATA (ID: 101092749). This work has received funding from the Horizon 2020 projects INFORE (ID: 825070) and PerMedCoE (ID: 951773) and from the Horizon Europe project CREXDATA (ID: 101092749). This work was funded in part by the French government under the management of Agence Nationale de la Recherche as part of the “Investissements d’avenir” programme, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Contribución de congreso (ConferenceOutput)

Lessons Learned from a Performance Analysis and Optimization of a Multiscale Cellular Simulation

  • Clasca, Marc
  • Garcia Gasulla, Marta|||0000-0003-3682-9905
  • Montagud, Arnau|||0000-0002-7696-1241
  • Carbonell Caballero, José
  • Valencia, Alfonso|||0000-0002-8937-6789
This work presents a comprehensive performance analysis and optimization of a multiscale agent-based cellular simulation. The optimizations applied are guided by detailed performance analysis and include memory management, load balance, and a locality-aware parallelization. The outcome of this paper is not only the speedup of 2.4x achieved by the optimized version with respect to the original PhysiCell code, but also the lessons learned and best practices when developing parallel HPC codes to obtain efficient and highly performant applications, especially in the computational biology field., This work has received funding from the EU Horizon 2020 POP2 (grant agreement No 824080), PerMedCoE (grant agreement No 951773), and by the Spanish Government(PID2019-107255GB)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Virtual clinical QT exposure-response studies – A translational computational approach

  • Aguado Sierra, Jazmín|||0000-0002-9711-3225
  • Dominguez Gomez, Paula
  • Amar, Ani
  • Butakoff, Constantine
  • Leitner, Michael
  • Schaper, Stefan
  • Kriegl, Jan M.
  • Darpo, Borje
  • Vázquez, Mariano|||0000-0002-2526-6708
  • Rast, Georg
Background and purpose A recent paradigm shift in proarrhythmic risk assessment suggests that the integration of clinical, non-clinical, and computational evidence can be used to reach a comprehensive understanding of the proarrhythmic potential of drug candidates. While current computational methodologies focus on predicting the incidence of proarrhythmic events after drug administration, the objective of this study is to predict concentration-response relationships of QTc as a clinical endpoint. Experimental approach Full heart computational models reproducing human cardiac populations were created to predict the concentration-response relationship of changes in the QT interval as recommended for clinical trials. The concentration-response relationship of the QT-interval prolongation obtained from the computational cardiac population was compared against the relationship from clinical trial data for a set of well-characterized compounds: moxifloxacin, dofetilide, verapamil, and ondansetron. Key results Computationally derived concentration–response relationships of QT interval changes for three of the four drugs had slopes within the confidence interval of clinical trials (dofetilide, moxifloxacin and verapamil) when compared to placebo-corrected concentration-ΔQT and concentration-ΔQT regressions. Moxifloxacin showed a higher intercept, outside the confidence interval of the clinical data, demonstrating that in this example, the standard linear regression does not appropriately capture the concentration-response reulsts at very low concentrations. The concentrations corresponding to a mean QTc prolongation of 10 ms were consistently lower in the computational model than in clinical data. The critical concentration varied within an approximate ratio of 0.5 (moxifloxacin and ondansetron) and 1 times (dofetilide, verapamil) the critical concentration observed in human clinical trials. Notably, no other in silico methodology can approximate the human critical concentration values for a QT interval prolongation of 10 ms. Conclusion and implications Computational concentration-response modelling of a virtual population of high-resolution, 3-dimensional cardiac models can provide comparable information to clinical data and could be used to complement pre-clinical and clinical safety packages. It provides access to an unlimited exposure range to support trial design and can improve the understanding of pre-clinical-clinical translation., JA-S is funded by a Ramon y Cajal fellowship (RYC-2017-22,532), Ministerio de Ciencia e Innovacion, Spain; and by Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion (meHeart ME PID2019-104356RB-C44). CB is funded by the Torres Quevedo Program (PTQ2018–010290), Ministerio de Ciencia e Innovacion, Spain. AA is funded by the Torres Quevedo Program (PTQ2020–011408), Ministerio de Ciencia e Innovacion, Spain. JA-S, and MV are supported by the European Union's Horizon 2020 research and innovation programme under grant agreements No. 823712 (CompBioMed project, phase 2) and No. 951773 (PerMedCoE). Elem Biotech research staff was supported by the RED.ES Spanish programme, under grant reference No 2021/C005/00149823, during the development phase of the project., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Contribución de congreso (ConferenceOutput)

Lessons Learned from a Performance Analysis and Optimization of a Multiscale Cellular Simulation

  • Clasca, Marc
  • Garcia Gasulla, Marta
  • Montagud, Arnau
  • Carbonell Caballero, José
  • Valencia, Alfonso
This work presents a comprehensive performance analysis and optimization of a multiscale agent-based cellular simulation. The optimizations applied are guided by detailed performance analysis and include memory management, load balance, and a locality-aware parallelization. The outcome of this paper is not only the speedup of 2.4x achieved by the optimized version with respect to the original PhysiCell code, but also the lessons learned and best practices when developing parallel HPC codes to obtain efficient and highly performant applications, especially in the computational biology field., This work has received funding from the EU Horizon 2020 POP2 (grant agreement No 824080), PerMedCoE (grant agreement No 951773), and by the Spanish Government(PID2019-107255GB)., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms

  • Ostaszewski, Marek
  • Niarakis, Anna
  • Mazein, Alexander
  • Kuperstein, Inna
  • Phair, Robert
  • Montagud, Arnau
  • Ponce De Leon, Miguel
  • Vazquez, Miguel
  • Valencia, Alfonso
We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS-CoV-2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large-scale community effort to build an open access, interoperable and computable repository of COVID-19 molecular mechanisms. The COVID-19 Disease Map (C19DMap) is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph-based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS-CoV-2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID-19 or similar pandemics in the long-term perspective., We would like to thank Andjela Tatarovic, architect, and Gina Crovetto, a researcher in the field of cancer, for their help with the design of the top-level view diagrams. We would like to acknowledge the Responsible and Reproducible Research (R3) team of the Luxembourg Centre for Systems Biomedicine for supporting the project and providing necessary communication and data sharing resources. The work presented in this paper was carried out using the ELIXIR Luxembourg tools and services. This study was supported by the Luxembourg National Research Fund (FNR) COVID-19 Fast-Track grant programme, grant COVID-19/2020-1/14715687/CovScreen (E. Glaab); European Commission, INFORE grant H2020-ICT-825070 (A. Montagud, M. Ponce de Leon, M. Vazques and A. Valencia); European Commission, PerMedCoE grant H2020-ICT-951773 (A. Montagud, M. Ponce de Leon, M. Vazques and A. Valencia) the Federal Ministry of Education and Research (BMBF, Germany) and the Baden-Württemberg Ministry of Science, the Excellence Strategy of the German Federal and State Governments (A. Renz); German Center for Infection Research (DZIF), grant no 8020708703 (A. Dräger); The Netherlands Organisation for Health Research and Development (ZonMw), grant no 10430012010015, (M. Kutmon, S. Coort, F. Ehrhart, N. Pham, E.L. Willighagen, C.T. Evelo); H2020 Marie Skłodowska-Curie Actions, grant number 765274 (J. Scheel); National Institutes of Health, USA (NIH), grant number U41 HG003751 (L.D. Stein). The development of Reactome is supported by grants from the US National Institutes of Health (U41 HG003751) and the European Molecular Biology Laboratory., Peer Reviewed, "Article signat per més de 50 autors/es: Marek Ostaszewski, Anna Niarakis, Alexander Mazein, Inna Kuperstein, Robert Phair, Aurelio Orta-Resendiz, Vidisha Singh, Sara Sadat Aghamiri, Marcio Luis Acencio, Enrico Glaab, Andreas Ruepp, Gisela Fobo, Corinna Montrone, Barbara Brauner, Goar Frishman, Luis Cristóbal Monraz Gómez, Julia Somers, Matti Hoch, Shailendra Kumar Gupta, Julia Scheel, Hanna Borlinghaus, Tobias Czauderna, Falk Schreiber, Arnau Montagud, Miguel Ponce de Leon, Akira Funahashi, Yusuke Hiki, Noriko Hiroi, Takahiro G Yamada, Andreas Dräger, Alina Renz, Muhammad Naveez, Zsolt Bocskei, Francesco Messina, Daniela Börnigen, Liam Fergusson, Marta Conti, Marius Rameil, Vanessa Nakonecnij, Jakob Vanhoefer, Leonard Schmiester, Muying Wang,Emily E Ackerman, Jason E Shoemaker, Jeremy Zucker, Kristie Oxford, Jeremy Teuton, Ebru Kocakaya, Gökçe Yağmur Summak, Kristina Hanspers, Martina Kutmon, Susan Coort, Lars Eijssen, Friederike Ehrhart, Devasahayam Arokia Balaya,Denise Slenter, Marvin Martens, Nhung Pham, Robin Haw, Bijay Jassal, Lisa Matthews, Marija Orlic-Milacic, Andrea Senff Ribeiro, Karen Rothfels, Veronica Shamovsky, Ralf Stephan, Cristoffer Sevilla, Thawfeek Varusai, Jean-Marie Ravel, Rupsha Fraser, Vera Ortseifen, Silvia Marchesi, Piotr Gawron, Ewa Smula, Laurent Heirendt, Venkata Satagopam, Guanming Wu, Anders Riutta, Martin Golebiewski, Stuart Owen51,Carole Goble, Xiaoming Hu, Rupert W Overall, Dieter Maier, Angela Bauch, Benjamin M Gyori, John A Bachman, Carlos Vega, Valentin Grouès, Miguel Vazquez, Pablo Porras, Luana Licata, Marta Iannuccelli, Francesca Sacco57, Anastasia Nesterova, Anton Yuryev, Anita de Waard, Denes Turei, Augustin Luna, Ozgun Babur, Sylvain Soliman, Alberto Valdeolivas, Marina Esteban-Medina, Maria Peña-Chilet, Kinza Rian, Tomáš Helikar, Bhanwar Lal Puniya, Dezso Modos, Agatha Treveil, Marton Olbei, Bertrand De Meulder, Stephane Ballereau, Aurélien Dugourd, Aurélien Naldi, Vincent Noël, Laurence Calzone, Chris Sander, Emek Demir, Tamas Korcsmaros, Tom C Freeman, Franck Augé, Jacques S Beckmann, Jan Hasenauer, Olaf Wolkenhauer, Egon L Wilighagen, Alexander R Pico, Chris T Evelo, Marc E Gillespie, Lincoln D Stein, Henning Hermjakob, Peter D'Eustachio, Julio Saez-Rodriguez, Joaquin Dopazo, Alfonso Valencia, Hiroaki Kitano, Emmanuel Barillot, Charles Auffray, Rudi Balling, Reinhard Schneider ", Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Systems Biology at the giga-scale: large multi-scale models of complex, heterogeneous multicellular systems

  • Montagud, Arnau
  • Ponce De Leon, Miguel
  • Valencia, Alfonso
Agent-based modelling has proven its usefulness in several biomedical projects by explaining and uncovering mechanisms in diseases. Nevertheless, the scenarios addressed in these models usually consider a small number of cells, lack cell-specific characterisation and dynamic interactions and have a simplistic environment description. Tools that enable scalable, real-sized simulations of biological systems that require complex set-ups are needed to have simulations closer to biomedical scenarios that can capture cell-to-cell heterogeneity and system-wide emerging properties. To deliver simulations at the giga-scale (109 cells), different tools have implemented technologies to run in high-performance computing clusters. We hereby review these efforts and detail the main areas of improvement the field needs to focus on to have simulations that are a step closer to having digital twins, This work has been partially supported by the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE project (H2020-ICT-951773)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Ostaszewski, Marek
  • Mazein, Alexander
  • Kuperstein, Inna
  • Kutmon, Martina
  • Montagud, Arnau
  • Ponce De Leon, Miguel
  • Valencia, Alfonso
The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms.Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue-or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No.10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “Away to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH)., Peer Reviewed, "Article signat per més de 50 autors/es: Anna Niarakis, Marek Ostaszewski, Alexander Mazein, Inna Kuperstein, Martina Kutmon, Marc E. Gillespie, Akira Funahashi, Marcio L. Acencio, Ahmed Hemedan, Michael Aichem, Karsten Klein, Tobias Czauderna, Felicia Burtscher, Takahiro G. Yamada, Yusuke Hiki, Noriko F. Hiroi, Finterly Hu, Nhung Pham, Friederike Ehrhart, Egon Willighagen, Alberto Valdeolivas, Aurelien Dugourd, Francesco Messina, Marina Esteban Medina, Maria Peña-Chilet, Kinza Rian, Sylvain Soliman, Sara S. Aghamiri, Bhanwar Lal Puniya, Aurélien Naldi, Tomáš Helikar, Vidisha Singh, Marco Fariñas Fernández, Viviam Bermudez, Eirini Tsirvouli, Arnau Montagud, Vincent Noël, Miguel Ponce De Leon, Dieter Maier, Angela Bauch, Benjamin M. Gyori, John A. Bachman, Augustin Luna, Janet Piñero, Laura I. Furlong, Irina Balaur, Adrien Rougny, Yohan Jarosz, Rupert W. Overall, Robert Phair, Livia Perfetto, Lisa Matthews, Devasahayam Arokia Balaya Rex, Marija Orlic-Milacic, Cristobal Luis, Bertrand De Meulder, Jean M. Ravel, Bijay Jassal, Venkata P. Satagopam, Guanming Wu, Martin Golebiewski, Piotr Gawron, Laurence Calzone, Jacques S. Beckmann, Chris Evelo, Peter D'eustachio, Falk Schreiber, Julio Saez-Rodriguez, Joaquin Dopazo, Martin Kuiper, Alfonso Valencia, Olaf Wolkenhauer, Hiroaki Kitano, Emmanuel Barillot, Charles Auffray, Rudi Balling, Reinhard Schneider ", Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optimizing dosage-specific treatments in a multi-Scale model of a tumor growth

  • Ponce De Leon, Miguel
  • Montagud, Arnau
  • Akasiadis, Charilaos
  • Schreiber, Janina
  • Ntiniakou, Thaleia
  • Valencia, Alfonso
The emergence of cell resistance in cancer treatment is a complex phenomenon that emerges from the interplay of processes that occur at different scales. For instance, molecular mechanisms and population-level dynamics such as competition and cell–cell variability have been described as playing a key role in the emergence and evolution of cell resistances. Multi-scale models are a useful tool for studying biology at very different times and spatial scales, as they can integrate different processes occurring at the molecular, cellular, and intercellular levels. In the present work, we use an extended hybrid multi-scale model of 3T3 fibroblast spheroid to perform a deep exploration of the parameter space of effective treatment strategies based on TNF pulses. To explore the parameter space of effective treatments in different scenarios and conditions, we have developed an HPC-optimized model exploration workflow based on EMEWS. We first studied the effect of the cells’ spatial distribution in the values of the treatment parameters by optimizing the supply strategies in 2D monolayers and 3D spheroids of different sizes. We later study the robustness of the effective treatments when heterogeneous populations of cells are considered. We found that our model exploration workflow can find effective treatments in all the studied conditions. Our results show that cells’ spatial geometry and population variability should be considered when optimizing treatment strategies in order to find robust parameter sets., This research has received funding from the Horizon 2020 INFORE Project, GA n° 825070 and the Horizon 2020 PerMedCoE Project, GA n° 951773., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Virtual clinical QT exposure-response studies – A translational computational approach

  • Aguado Sierra, Jazmín
  • Dominguez Gomez, Paula
  • Amar, Ani
  • Butakoff, Constantine
  • Leitner, Michael
  • Schaper, Stefan
  • Kriegl, Jan M.
  • Darpo, Borje
  • Vázquez, Mariano
  • Rast, Georg
Background and purpose A recent paradigm shift in proarrhythmic risk assessment suggests that the integration of clinical, non-clinical, and computational evidence can be used to reach a comprehensive understanding of the proarrhythmic potential of drug candidates. While current computational methodologies focus on predicting the incidence of proarrhythmic events after drug administration, the objective of this study is to predict concentration-response relationships of QTc as a clinical endpoint. Experimental approach Full heart computational models reproducing human cardiac populations were created to predict the concentration-response relationship of changes in the QT interval as recommended for clinical trials. The concentration-response relationship of the QT-interval prolongation obtained from the computational cardiac population was compared against the relationship from clinical trial data for a set of well-characterized compounds: moxifloxacin, dofetilide, verapamil, and ondansetron. Key results Computationally derived concentration–response relationships of QT interval changes for three of the four drugs had slopes within the confidence interval of clinical trials (dofetilide, moxifloxacin and verapamil) when compared to placebo-corrected concentration-ΔQT and concentration-ΔQT regressions. Moxifloxacin showed a higher intercept, outside the confidence interval of the clinical data, demonstrating that in this example, the standard linear regression does not appropriately capture the concentration-response reulsts at very low concentrations. The concentrations corresponding to a mean QTc prolongation of 10 ms were consistently lower in the computational model than in clinical data. The critical concentration varied within an approximate ratio of 0.5 (moxifloxacin and ondansetron) and 1 times (dofetilide, verapamil) the critical concentration observed in human clinical trials. Notably, no other in silico methodology can approximate the human critical concentration values for a QT interval prolongation of 10 ms. Conclusion and implications Computational concentration-response modelling of a virtual population of high-resolution, 3-dimensional cardiac models can provide comparable information to clinical data and could be used to complement pre-clinical and clinical safety packages. It provides access to an unlimited exposure range to support trial design and can improve the understanding of pre-clinical-clinical translation., JA-S is funded by a Ramon y Cajal fellowship (RYC-2017-22,532), Ministerio de Ciencia e Innovacion, Spain; and by Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion (meHeart ME PID2019-104356RB-C44). CB is funded by the Torres Quevedo Program (PTQ2018–010290), Ministerio de Ciencia e Innovacion, Spain. AA is funded by the Torres Quevedo Program (PTQ2020–011408), Ministerio de Ciencia e Innovacion, Spain. JA-S, and MV are supported by the European Union's Horizon 2020 research and innovation programme under grant agreements No. 823712 (CompBioMed project, phase 2) and No. 951773 (PerMedCoE). Elem Biotech research staff was supported by the RED.ES Spanish programme, under grant reference No 2021/C005/00149823, during the development phase of the project., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Contribución de congreso (ConferenceOutput)

BioFVM-X: an MPI+OpenMP 3-D simulator for biological systems

  • Saxena, Gaurav
  • Ponce De Leon, Miguel
  • Montagud, Arnau
  • Vicente Dorca, David
  • Valencia, Alfonso
Multi-scale simulations require parallelization to address large-scale problems, such as real-sized tumor simulations. BioFVM is a software package that solves diffusive transport Partial Differential Equations for 3-D biological simulations successfully applied to tissue and cancer biology problems. Currently, BioFVM is only shared-memory parallelized using OpenMP, greatly limiting the execution of large-scale jobs in HPC clusters. We present BioFVM-X: an enhanced version of BioFVM capable of running on multiple nodes. BioFVM-X uses MPI+OpenMP to parallelize the generic core kernels of BioFVM and shows promising scalability in large 3-D problems with several hundreds diffusible substrates and ≈ 0.5 billion voxels. The BioFVM-X source code, examples and documentation, are available under the BSD 3-Clause license at https://gitlab.bsc.es/gsaxena/biofvm_x., The research leading to these results has received funding from EU H2020 Programme under the PerMedCoE project, grant agreement number 951773 and the INFORE project, grant agreement number 825070. The authors would like to thank Paul Macklin and Randy Heiland from Indiana University for their constant support and advice regarding BioFVM., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • COVID-19 Disease Map Community
Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks

  • Ponce De Leon, Miguel
  • Montagud, Arnau
  • Noël, Vincent
  • Meert, Annika
  • Pradas, Gerard
  • Barillot, Emmanuel
  • Calzone, Laurence
  • Valencia, Alfonso
In systems biology, mathematical models and simulations play a crucial role in understanding complex biological systems. Different modelling frameworks are employed depending on the nature and scales of the system under study. For instance, signalling and regulatory networks can be simulated using Boolean modelling, whereas multicellular systems can be studied using agent-based modelling. Herein, we present PhysiBoSS 2.0, a hybrid agent-based modelling framework that allows simulating signalling and regulatory networks within individual cell agents. PhysiBoSS 2.0 is a redesign and reimplementation of PhysiBoSS 1.0 and was conceived as an add-on that expands the PhysiCell functionalities by enabling the simulation of intracellular cell signalling using MaBoSS while keeping a decoupled, maintainable and model-agnostic design. PhysiBoSS 2.0 also expands the set of functionalities offered to the users, including custom models and cell specifications, mechanistic submodels of substrate internalisation and detailed control over simulation parameters. Together with PhysiBoSS 2.0, we introduce PCTK, a Python package developed for handling and processing simulation outputs, and generating summary plots and 3D renders. PhysiBoSS 2.0 allows studying the interplay between the microenvironment, the signalling pathways that control cellular processes and population dynamics, suitable for modelling cancer. We show different approaches for integrating Boolean networks into multi-scale simulations using strategies to study the drug effects and synergies in models of cancer cell lines and validate them using experimental data. PhysiBoSS 2.0 is open-source and publicly available on GitHub with several repositories of accompanying interoperable tools., The authors thank Paul Macklin and Randy Heiland for their support with the PhysiCell code and discussions. The authors acknowledge the technical expertise and assistance provided by the Spanish Supercomputing Network (Red Española de Supercomputación), as well as the computer resources used: the LaPalma Supercomputer (RES-BCV-2019-2-0008), located at the Instituto de Astrofísica de Canarias, and MareNostrum4 (RES-BCV-2019-2-0013, RES-BCV-2020-3-0016, RES-BCV-2021-2-0020), located at the Barcelona Supercomputing Center. This work has received funding from the Horizon 2020 projects: INFORE (ID: 825070), PerMedCoE (ID: 951773) and CREXDATA (ID: 101092749). This work has received funding from the Horizon 2020 projects INFORE (ID: 825070) and PerMedCoE (ID: 951773) and from the Horizon Europe project CREXDATA (ID: 101092749). This work was funded in part by the French government under the management of Agence Nationale de la Recherche as part of the “Investissements d’avenir” programme, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Patient-specific Boolean models of signalling networks guide personalised treatments

  • Montagud, Arnau
  • Béal, Jonas
  • Tobalina, Luis
  • Traynard, Pauline
  • Subramanian, Vigneshwari
  • Valencia, Alfonso
Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell-line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell-line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology., This work has been partially supported by the European Commission under the PrECISE project (H2020-PHC-668858), the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773), Peer Reviewed, "Article signat per 12 autors/es: Arnau Montagud, Jonas Béal, Luis Tobalina, Pauline Traynard, Vigneshwari Subramanian, Bence Szalai, Róbert Alföldi, László Puskás, Alfonso Valencia, Emmanuel Barillot, Julio Saez-Rodriguez, Laurence Calzone", Postprint (author's final draft)